Johnson Dunn Capital Advisors Inc’s Akebia Therapeutics AKBA Stock Holding History

Johnson Dunn Capital Advisors Inc’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$11.2K	Buy	+12,200	New	+$13.1K	0.01%	155

Other funds holding AKBA

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Johnson Dunn Capital Advisors Inc's AKBA Position: Q3 2026 in Review

Johnson Dunn Capital Advisors Inc opened a new position in Akebia Therapeutics (AKBA) in Q3 2026: 12,200 shares worth $11.2K. The stake represents 0.01% of the portfolio and ranks #155 among its holdings.

97 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

Johnson Dunn Capital Advisors Inc held 12,200 shares of Akebia Therapeutics worth $11.2K as of Q3 2026.
Akebia Therapeutics was a new Johnson Dunn Capital Advisors Inc position in Q3 2026.
Akebia Therapeutics made up 0.01% of Johnson Dunn Capital Advisors Inc's portfolio in Q3 2026, its #155 holding.
97 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Johnson Dunn Capital Advisors Inc's 13F filing for Q3 2026, filed 12 Nov 2026.